Evidence map›Paper›PMID 25249672›Full record

ArticleDiabetes care2014

Diabetic kidney disease: a report from an ADA Consensus Conference.

Katherine R Tuttle, George L Bakris, Rudolf W Bilous, Jane L Chiang, Ian H de Boer, Jordi Goldstein-Fuchs, Irl B Hirsch, Kamyar Kalantar-Zadeh, Andrew S Narva, Sankar D Navaneethan and 5 more

2 registry-linked trialsOpen access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 560 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
560citing papers in PubMed, 9 pooled it
29.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02996539 completednot on this map

Heart Rate Variability and Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients

TypeobservationalSponsorShi wei, MMRan2013 to 2015Enrolled392ConditionsType2 Diabetes MellitusArmsClinical examination and laboratory measurements
NCT03622957 unknown statusnot on this mapstarted 2018, after this paper: background citation

Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - Protocol 2

TypeobservationalSponsorUniversity of PisaRan2018 to 2018Enrolled200ConditionsDiabetes Mellitus, Type 2, Albuminuria, Cardiovascular Risk Factor
3 · Its place in the literature

Who cites it

560 citing papers in PubMed, 9 syntheses or guidelines pooled it, 1,108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Characteristics and quality of clinical practice guidelines for diabetic kidney disease: a systematic review.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

500 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 2 countries.

Katherine R TuttleUniversity of Washington School of Medicine, Seattle, WA, and Providence Health Care, Spokane, WA.
George L BakrisComprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL (National Kidney Foundation liaison).
Rudolf W BilousNewcastle University, Newcastle upon Tyne, U.K.
Jane L ChiangAmerican Diabetes Association, Alexandria, VA jchiang@diabetes.org.
Ian H de BoerDivision of Nephrology, University of Washington, Seattle, WA.
Jordi Goldstein-FuchsSierra Nevada Nephrology Consultants, Reno, NV.
Irl B HirschDivision of Metabolism, Endocrinology and Nutrition, University of Washington School of Medicine, Seattle, WA.
Kamyar Kalantar-ZadehSchool of Medicine, University of California, Irvine, Irvine, CA.
Andrew S NarvaNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Sankar D NavaneethanDepartment of Nephrology and Hypertension, Novick Center for Clinical and Translational Research, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Joshua J NeumillerDepartment of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA.
Uptal D PatelDivisions of Nephrology and Pediatric Nephrology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (American Society of Nephrology liaison).
Robert E RatnerAmerican Diabetes Association, Alexandria, VA.
Adam T Whaley-ConnellHarry S. Truman Memorial Veterans Hospital, Columbia, MO, and Department of Internal Medicine, Division of Nephrology and Hypertension, University of Missouri School of Medicine, Columbia, MO.
Mark E MolitchDivision of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
University of Washington · USAmerican Diabetes Association · USAmerican Society of Nephrology · USCleveland Clinic · USHarry S. Truman Memorial Veterans' Hospital · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Kidney Foundation · USNewcastle University · GBNorthwestern University · USSierra Nevada Corporation (United States) · USUniversity of California, Irvine · USWashington State University Spokane · US

Funding

Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
NCATS NIH HHS UL1 TR000430
6 · The paper itself

Abstract

The incidence and prevalence of diabetes mellitus have grown significantly throughout the world, due primarily to the increase in type 2 diabetes. This overall increase in the number of people with diabetes has had a major impact on development of diabetic kidney disease (DKD), one of the most frequent complications of both types of diabetes. DKD is the leading cause of end-stage renal disease (ESRD), accounting for approximately 50% of cases in the developed world. Although incidence rates for ESRD attributable to DKD have recently stabilized, these rates continue to rise in high-risk groups such as middle-aged African Americans, Native Americans, and Hispanics. The costs of care for people with DKD are extraordinarily high. In the Medicare population alone, DKD-related expenditures among this mostly older group were nearly $25 billion in 2011. Due to the high human and societal costs, the Consensus Conference on Chronic Kidney Disease and Diabetes was convened by the American Diabetes Association in collaboration with the American Society of Nephrology and the National Kidney Foundation to appraise issues regarding patient management, highlighting current practices and new directions. Major topic areas in DKD included 1) identification and monitoring, 2) cardiovascular disease and management of dyslipidemia, 3) hypertension and use of renin-angiotensin-aldosterone system blockade and mineralocorticoid receptor blockade, 4) glycemia measurement, hypoglycemia, and drug therapies, 5) nutrition and general care in advanced-stage chronic kidney disease, 6) children and adolescents, and 7) multidisciplinary approaches and medical home models for health care delivery. This current state summary and research recommendations are designed to guide advances in care and the generation of new knowledge that will meaningfully improve life for people with DKD.

Indexed as

Diabetic NephropathiesAdolescentAgedAntihypertensive AgentsBlood GlucoseCardiovascular DiseasesChildDiabetes Mellitus, Type 2HumansIncidenceKidney Function TestsMiddle AgedPrevalenceRenal Insufficiency, ChronicAntihypertensive AgentsBlood Glucose

Identifiers

PMID25249672
PMCPMC4170131
OpenAlexW2072070798

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.